GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camp4 Therapeutics Corp (NAS:CAMP) » Definitions » EBITDA Margin %

CAMP (Camp4 Therapeutics) EBITDA Margin % : -2,088.34% (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Camp4 Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Camp4 Therapeutics's EBITDA for the three months ended in Dec. 2024 was $-13.62 Mil. Camp4 Therapeutics's Revenue for the three months ended in Dec. 2024 was $0.65 Mil. Therefore, Camp4 Therapeutics's EBITDA margin for the quarter that ended in Dec. 2024 was -2,088.34%.


Camp4 Therapeutics EBITDA Margin % Historical Data

The historical data trend for Camp4 Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Camp4 Therapeutics EBITDA Margin % Chart

Camp4 Therapeutics Annual Data
Trend Dec22 Dec23 Dec24
EBITDA Margin %
- -14,343.14 -7,882.21

Camp4 Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Jun24 Sep24 Dec24
EBITDA Margin % Get a 7-Day Free Trial -3,402.29 - - - -2,088.34

Competitive Comparison of Camp4 Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, Camp4 Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Camp4 Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Camp4 Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Camp4 Therapeutics's EBITDA Margin % falls into.


;
;

Camp4 Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Camp4 Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-51.392/0.652
=-7,882.21 %

Camp4 Therapeutics's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-13.616/0.652
=-2,088.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Camp4 Therapeutics  (NAS:CAMP) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Camp4 Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Camp4 Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Camp4 Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA, USA
Camp4 Therapeutics Corp is a clinical stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.